News | September 20, 2013

New York Proton Consortium Expands Access To Proton Therapy Through Agreement With Procure Proton Therapy Center In New Jersey

The New York Proton Center (NYPC), a consortium of five leading hospitals in New York City, including Continuum Health Partners, Memorial Sloan-Kettering Cancer Center, Montefiore Medical Center, the Mount Sinai Medical Center, and New York University Langone Medical Center, announced an agreement with ProCure Proton Therapy Center in Somerset, N.J., CentraState Health Care System, Princeton Radiation Oncology  and management services for NYPC being provided by 21st Century Oncology, a national provider of advanced radiation oncology services. This agreement will give the consortium’s patients access to a state-of-the-art proton treatment center in Somerset, N.J., one of only twelve such centers in the nation and the only center in the New York and New Jersey region. Proton therapy is a unique form of precision radiation that directly attacks tumors while minimizing potentially damaging radiation to surrounding healthy tissues and organs.

The NYPC consortium noted in a brief statement that they are "deeply committed to providing the highest standard of care to cancer patients, which includes access to proton therapy. For certain patients, especially those with solid tumors surrounded by sensitive tissue and vital organs, proton therapy is often the treatment of choice."   

Studies have shown proton therapy to be effective in treating many types of tumors, including pediatric cancers and selected tumors of the head and neck, brain, spinalcord, breast, gastrointestinal system, lung and prostate.

Unlike traditional X-ray beams that deposit a dose of radiation all the way through the patient’s body, proton beams stop abruptly and do not deliver radiation dose beyond the tumor.  In many cases, this unique property of protons allows physicians to concentrate radiation within the tumor while reducing the dose to surrounding tissues with greater precision than can be achieved with conventional radiation beams, thereby reducing the risk of side effects and improving the patient’s quality of life.  

Recognizing these benefits of proton therapy for patients with specific tumor types, NYPC’s agreement with the ProCure Proton Therapy Center allows this therapy to be conveniently accessible for their patients. Under the agreement, patients receiving care at NYPC hospitals who need proton therapy will continue to have their treatments provided by their physicians who will now have treatment privileges at the Proton Center.

“It has always been the Mission of ProCure and our affiliate CentraState Healthcare System to make proton therapy available to as many patients as possible,” said Oren Cahlon, M.D., of Princeton Radiation Oncology, medical director of the ProCure Proton Therapy Center in Somerset, N.J. “Our agreement with NYPC allows us to share our access to proton therapy and takes us one step closer to fulfilling our mission.”

The ProCure Proton Therapy Center in Somerset, N.J., in affiliation with CentraState Healthcare System and Princeton Radiation Oncology, opened in March 2012.

For more information: www.procure.com

Related Content

Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy
Technology | Proton Therapy | January 04, 2018
Mevion Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Mevion S250i...
MEDraysintell Downgrades Proton Therapy Market Projection for 2030
News | Proton Therapy | January 02, 2018
MEDraysintell recently downgraded its projection for proton therapy rooms expected to be operational in 2030 from 1,200...
RaySearch Releases RayStation 7 Radiotherapy Treatment Planning System
Technology | Treatment Planning | December 19, 2017
RayStation 7, the latest release of RaySearch’s radiation therapy treatment planning system, adds new functionality and...
Baptist Hospital's Miami Cancer Institute Treats First Patient With Proteus Plus Proton Therapy
News | Proton Therapy | December 19, 2017
December 19, 2017 — IBA (Ion Beam Applications SA) announced that Miami Cancer Institute treated its first patients,
Mevion Achieves CE Mark for S250i Proton Therapy System
News | Proton Therapy | November 21, 2017
November 21, 2017 — Mevion Medical Systems announced the Mevion S250i...
RayStation Selected for New Tennessee Proton Therapy Center
News | Treatment Planning | November 20, 2017
November 20, 2017 — Provision Healthcare has selected RayStation for external beam planning at the new Provision Care
Proton therapy doesn’t get as near to the heart and other internal organs as X-ray therapy does. (Image courtesy of Provision Cares Proton Therapy Center.)

Proton therapy doesn’t get as near to the heart and other internal organs as X-ray therapy does. (Image courtesy of Provision Cares Proton Therapy Center.)

Feature | Proton Therapy | November 06, 2017 | By Larisa Brass, MPH
Thirty-three. Twenty-nine. Sixty-four. These are the ages of the breast cancer patients who have walked through the...
PTCOG-NA Studies Address Cost and Coverage Issues With Proton Therapy
News | Proton Therapy | November 01, 2017
Physicians from across the country gathered in Chicago last week to discuss the most recent advances in proton therapy...
Proton Therapy Lowers Treatment Side Effects in Pediatric Head and Neck Cancer Patients
News | Proton Therapy | November 01, 2017
Pediatric patients with head and neck cancer can be treated with proton beam therapy (PBT) instead of traditional...
Proton Therapy Shows Promising Clinical Benefits for Esophageal, Prostate and Breast Cancer
News | Proton Therapy | October 30, 2017
The National Association for Proton Therapy (NAPT) announced a number of clinical papers showing promising results were...
Overlay Init